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Introduction
It is widely recognized diabetes represents a relevant 
public health issue worldwide, due to the remarkable 
social, economic and healthcare burden this disorder 
is responsible for, mainly through the development of 
chronic complications leading to increased morbidity 
and mortality in the affected individuals [1].
Diabetes-associated burden has been progressively be-
coming even more relevant, due to the overwhelming 
increase in the number of patients diagnosed with this 
disorder which has already attained the status of an 
epidemic condition, as demonstrated by the doubling 
of people living with diabetes observed over the last 
two years, reaching, overall, 415 million of individuals 
worldwide, in 2015 [2].
Notably, as reported by the International Diabetes Fed-
eration (IDF), such a trend is expected to continue over 
the next years, even to a greater extent, with estimates 
indicating a further increase in the number of subjects 
suffering from diabetes reaching 642 million by 2040 
worldwide [2].
Increased likelihood of infections  
in diabetic patients
There’s increasing body of evidence supporting diabetes 
leads to an increased risk of developing and dying from 
infectious diseases [3-5].
It has been shown that certain infectious diseases, such 
as influenza, not only are more likely to occur in dia-
betes patients, but may generally have a more severe 
course (e.g., higher incidence of complications) in this 
patient group [4].
In fact, as compared to subjects with normal glucose 
metabolism, diabetics have been shown a higher relative 
risk (RR) for infection-related adverse outcomes such as 
hospitalization [RR: 2.17 (p < 0,0001)] or death [RR: 
1.92 (p < 0,0001)] [6].
Multiple mechanisms may account for the increased risk 
of infections in patients with diabetes (Fig. 1), most of 
them related to chronic hyperglycemia which may affect 
several physiological pathways involved in the immune 
response against pathogens which virulence also appear 
to be higher in diabetics [3-5].
It has been described that also comorbidities, such as 
obesity (which often affects diabetic subjects), may con-
tribute to pose individuals with diabetes at increased risk 
of developing infectious diseases [3, 4, 6].
Fig. 1. Pathophysiology of infections associated with diabetes 
mellitus [3].
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The major points of interest are:
• Diabetes is associated with an increased likelihood of 
infections [3-5]. 
• Multiple factors appear to be involved in diabetic pa-
tients’ increased risk to infections [3-5].
• Infectious diseases’ course is likely to be more severe 
in diabetics, with higher risk for hospitalization and 
death compared to euglycemic subjects [6].
Influenza infection in patients  
with diabetes
Susceptibility to & burden of influenza,  
and vaccination-related benefits
Influenza infection has been shown to affect patients 
with diabetes to a greater extent than it does with indi-
viduals with normal glucose homeostasis, as highlighted 
by available literature [3, 4].
Subjects with diabetes not only have an increased risk 
to develop influenza during winter season, but they’re 
more likely to experience a more severe course of this 
infection, as compared to general population, with high-
er incidence of flu-related major adverse outcomes such 
as all-cause hospitalizations, intensive care unit admis-
sions, and all-cause mortality, as well [7-9].
Notably, these findings have been reported not only in 
diabetic elderly patients, but also in younger diabetics, 
as well as in both subjects with type 1 and those with 
type 2 diabetes [7-9].
The higher risk for severe/complicated flu in diabetic 
patients has been reported not only by published studies, 
but arises also from real-life surveillance data from, for 
example, 2017-2018 flu season in Italy, where the ma-
jority of individuals either hospitalized at intensive care 
unit or died due to laboratory-confirmed influenza suf-
fered from at least a chronic disorder such as diabetes, 
COPD, cardiovascular disease [10].
Importantly, these subjects were younger than 65 years, 
having a mean age of 60 years, therefore, for whom 
recommendations by health authorities and scientific 
societies to get vaccinated against flu derives from the 
presence of a chronic disease (e.g., diabetes), rather than 
their age [10-13].
The increased severity of seasonal flu seen in patients 
with diabetes may, at least partially, result from influen-
za-associated deleterious impact on cardiovascular sys-
tem. In fact, as reported by a recently published study by 
Kwong et al., a relevant association between laboratory-
confirmed influenza and the likelihood of acute myocar-
dial infarction (AMI) occurrence after laboratory confir-
mation was found. Indeed, study subjects (half of whom 
suffered from diabetes) showed a six-fold increased risk 
to develop AMI within 7 days after confirmed influenza 
which, interestingly, was mainly driven by influenza B 
which accounted for a ten-fold increased risk of AMI, 
overall, whereas influenza A was associated with a five-
fold increased risk, accordingly [14].
Several mechanisms have been hypothesized to account 
for such an increased risk to develop AMI following in-
fluenza infection, especially in at-high cardiovascular 
risk individuals such as diabetics [15]. These mecha-
nisms –  leading to a worsening of atherosclerotic pro-
cess – include cytokine release during acute inflamma-
tion, atherosclerotic plaque damage, hypoxia, tachycar-
dia, vasoconstriction (following sympathetic system ac-
tivation), as well as a direct harmful effect by influenza 
virus on myocardial tissue (Fig. 2) [15].
Influenza vaccination has been shown to be beneficial 
to diabetic patients, as reported by available studies 
conducted in this at-risk group for flu-related compli-
cations [1]. Initial evidences supporting flu vaccination-
induced benefits in subjects with diabetes came from a 
UK study performed by Colquhoun et al. that clearly 
demonstrated a relevant relative risk reduction (i.e., by 
79%) in hospitalization due to influenza, pneumonia, 
bronchitis, as well as diabetic ketoacidosis and diabetes 
without complications, over two flu seasons [16]. Find-
ings from Colquhoun’s et al. study were consistent with 
results from more recently published studies which re-
ported improved outcomes in diabetic subjects, across 
different age, after receiving flu vaccination [17, 18].
Accordingly, Vamos & Coll. found how influenza vac-
cination, administered to over 120,000 type 2 diabetes 
patients, resulted in a significant relative risk (RR) re-
duction in major outcomes such as hospitalization due to 
stroke (-30%) (RR: 0.70; 95% confidence interval [CI]: 
0.53-0.91), heart failure (-22%) (RR: 0.78; 95% CI: 
0.65-0.92), pneumonia or influenza (-15%) (RR: 0.85; 
95%CI: 0.74-0.99), and all-cause mortality (-24%) (RR: 
0.76; 95%CI: 0.65-0.83) [17].
It has been shown as also diabetic elderly patient, a wide-
ly represented sub-group in daily clinical practice, may 
really benefit from getting vaccinated against seasonal 
flu, as reported by Kuan Wang et al. who found signifi-
cantly lower incidence of pneumonia, influenza, respira-
tory failure, as well as reduced risk for hospitalization, 
intensive care unit admission and death in vaccinated vs. 
not-vaccinated elderly subjects with diabetes [18].
Protection provided by flu vaccination against influenza 
virus-induced harmful impact (either direct or indirect) 
on myocardial tissue may account for the reported im-
Fig. 2. Mechanisms by which influenza may precipitate an acute 
myocardial infarction [15].
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provement of cardiovascular (CV) outcomes in patients 
with diabetes. This hypothesis may be supported by the 
flu vaccination’s marked effectiveness in the secondary 
prevention of AMI occurrence in high CV-risk patients, 
which was similar to that reported by well-established 
CV preventive interventions such as smoking cessation, 
antihypertensive drugs, statins (Tab. I) [15].
It is important to point out as, although the above-
mentioned impairment in the immune response seen in 
diabetic patients (accounting for their increased risk to 
experience severe flu), the latter have been shown to re-
ally benefit from receiving flu vaccination, being able to 
achieve an effective and sustained humoral immune re-
sponse to flu vaccine, similar to that observed in subjects 
without diabetes [1, 19].
Recommendations by health authorities/
scientific societies and current coverage 
rates 
Because of the flu-related relevant burden as well as well-
established vaccination-associated benefits in diabetic 
subjects, both international and national bodies - such 
as the Italian Ministry of Health (MoH), and Diabetes 
Scientific Societies (i.e., AMD & SID) recommended 
that all individuals with diabetes (either type 1 or type 2) 
above 6 months of age would receive seasonal influenza 
vaccination to protect themselves against flu-associated 
adverse outcomes [11-13].
As reported in both the 2017-2019 National Immuniza-
tion Plan (NIP) and Italian MoH’s recommendations for 
2018-2019 flu season, subjects with diabetes (as well as 
other chronic patients) will receive seasonal influenza 
vaccination via an active and free offer, being individu-
als at higher risk to develop flu-related morbidity and 
mortality [11, 12]. Both Italian MoH’s 2018-2019 rec-
ommendations and 2017-2019 NIP recommend for 
patients with diabetes (and, in general, for those with 
chronic disorders) to achieve flu vaccination coverage 
rates of at least 75% (i.e., minimum recommended tar-
get), or, ideally, the value of 95% representing the opti-
mal coverage goal for all at-risk individuals, regardless 
of their underlying disease [11, 12].
Nevertheless, despite influenza-associated burden and 
proven vaccination efficacy in improving major out-
comes in diabetic patients aged 18-64 years, the current 
coverage rates in this patient group are still low (~29%), 
far away from the aforementioned MoH’s recommended 
targets (Fig. 3) [12, 20].
Whereas, current influenza vaccination coverage rates in 
individuals with diabetes aged ≥ 65 years are unknown, 
so far (as other chronic conditions), since, to date, in 
Italy, for elderly people there’s information only about 
the overall flu vaccination coverage rates (which were 
around 52% in 2016-2017 season), with no data avail-
able for each chronic disorder in this age group [12].
Patients’ attitudes and/or barriers to flu 
vaccination
Patients’ attitudes towards medical interventions - either 
therapeutic (i.e., pharmacological treatments) or preven-
tive (i.e., vaccinations) - have been shown to play a key 
role to guarantee good patients’ compliance, and there-
fore increase the likelihood that these interventions are 
successful.
Available literature has shown that multiple patient-
related factors – including not being considered as at-
risk individuals for flu-associated complications, fear of 
vaccine-associated side effects, low awareness/knowl-
edge of vaccination-induced benefits – may account for 
influenza vaccination lower uptake among patients with 
diabetes [21].
On the other hand, advanced age, regular contacts with 
diabetes-treating physicians, more frequent visits at GP’s 
office, higher number of previous influenza vaccinations, 
existing comorbidities (e.g., chronic respiratory disor-
ders), longstanding diabetes, represented major factors 
associated with a higher likelihood to diabetic subjects 
to adhere to seasonal influenza vaccination  [21, 22].
The above-mentioned findings highlight the critical role 
GPs and diabetes-treating physicians play to effectively 
promote influenza vaccination uptake among their dia-
betic patients [21, 22].
The key role played, in Italy, by both diabetes-treating 
physicians and GPs to promote diabetics’ adherence to 
Tab. I. Efficacy of accepted coronary interventions and influenza vac-
cine in the prevention of myocardial infarction [15].
Coronary intervention Prevention Intervention
efficacy/
effectiveness
against acute
myocardial 
infarction (%)
Smoking cessation [4, 23-25] Secondary 32-43
Statins [38] Secondary 19-30
Antihypertensive drugs [26-29, 32] Secondary 17-25
Influenza vaccine [5, 9, 18] Secondary 15-45
Fig 3. Influenza vaccination coverage rates in patients with 
chronic disorders in Italy between 2014 and 2017 [20].
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this vaccination has also resulted from an Italian-based 
research (published in 2017) carried out by Censis In-
stitute, aiming at addressing knowledge/awareness, at-
titudes and behaviors of Italian people aged above 50 
years with regard to influenza and the related vaccina-
tion  [23]. The Censis research reported both influenza 
infection and flu vaccination were widely known by 
population involved, whereas less than 50% of the sam-
ple (i.e., 43%, overall) was aware of influenza-associat-
ed complications [23]. Moreover, this research clearly 
highlighted, according to 2016-2017 flu season data, 
that GPs play a key role, not only to administer flu vac-
cine, but also to actively promote patients/citizens’ ad-
herence to seasonal influenza vaccination (as reported 
by 63% of the interviewers) [23].
In summary the major points of interest are:
• Diabetic patients are more likely to experience severe 
influenza [3, 4].
• Diabetes confers an increased risk of acute myocar-
dial infarction, admission to intensive care unit, as 
well as all-cause hospitalization and mortality fol-
lowing influenza infection [8, 9, 14].
• Vaccination against influenza results in improved 
outcomes in diabetics (including the elderly), lead-
ing to a reduced risk of hospitalization due to stroke, 
heart failure and flu/pneumonia, respiratory failure 
onset all-cause mortality [16, 18].
• Flu vaccination has been shown to be as effective as 
well-known CV preventive interventions to reduce 
the risk of acute myocardial infarction in high-CV 
risk patients [15].
• Although marked flu burden and established vacci-
nation benefits, current coverage rates in diabetics < 
65 years are less than 30% [8, 17, 20].
• 2017 Censis report and available literature have 
shown that advice from both diabetes-treating physi-
cians and GPs are major factor to promote diabetic 
subjects’ adherence to flu vaccination [21-23].
Pneumococcal infections in subjects  
with diabetes
Susceptibility to & impact of pneumococcal 
infections, and vaccination-associated 
benefits
Patients with diabetes have been shown to have a higher 
likelihood to experience pneumococcal-related infec-
tions such as pneumococcal pneumonia (1.4 fold in-
crease) and pneumococcal invasive disease (1.4 to 1.6 
fold increase), both responsible for increased rates of 
morbidity and mortality, as well as relevant costs for 
healthcare system [24, 25].
Hyperglycemia-induced deleterious effects on immune 
and/or pulmonary function has been hypothesized to ac-
count for diabetes patients’ greater susceptibility to de-
velop both pneumococcal pneumonia and pneumococ-
cal invasive disease [24].
Notably, longstanding diabetes and poor glycemic con-
trol have been shown by available literature to account 
for an increased risk of hospitalization due to pneumo-
coccal pneumonia in diabetic individuals [24].
A recently published retrospective Spanish study – in-
cluding over 900,000 hospitalizations due to community 
acquired pneumonia (CAP), evaluated over 10 years –
reported an increased incidence of hospitalizations, over 
this period, among diabetic patients compared with indi-
viduals with normal glucose metabolism [26].
Pneumococcal-associated diseases have been shown to 
be responsible for a high economic burden, with total 
direct costs of 3,7 billion of dollars yearly in U.S. adults 
aged > 50 years [11].
In this regard, the European Respiratory Society report-
ed pneumonia-related costs to be higher than 10 billion 
of Euros within 51 European countries of WHO, with 
hospitalization-associated costs accounting for 6 billion 
of Euros yearly [11]. Because of the high clinical and 
economic burden of pneumococcal-related infections 
in diabetic patients, it is widely recognized the key role 
by pneumococcal vaccination to prevent pneumococcal 
infections-associated burden in these at-risk individuals.
Benefits associated with pneumococcal vaccination in 
diabetic patients have been reported by a randomized, 
placebo-controlled Dutch study, called CAPiTA (Com-
munity-Acquired Pneumonia Immunization Trial in 
Adults), which involved around 85,000 elderly sub-
jects with chronic disorders (half of whom with diabe-
tes) [25]. In fact, Suaya et al. showed 13-valent pneumo-
coccal conjugate vaccine (PCV13) was associated with 
higher and sustained (over a 4-year period) efficacy than 
placebo in preventing both the first and all pneumococ-
cal pneumonia episodes in subjects aged ≥ 65 years with 
chronic conditions, including diabetes [25].
Pneumococcal vaccination efficacy in diabetes patients 
has also been shown by a retrospective cohort study con-
ducted in approximately 67,000 elderly subjects that, 
via assessing, across a 9-year period, the Taiwanese Na-
tional Health Insurance Research Database, reported a 
reduced risk by 14% of pneumococcal invasive disease 
onset in the group who received 23-valent pneumococ-
cal vaccine (PPV23) compared with the group not ex-
posed to PPV23 [27].
Such a trial reported further benefits associated with 
Pneumococcal vaccination, since study subjects who re-
ceived PPV23 experienced an improvement in – clinical 
and economic – outcomes such as hospitalization, res-
piratory failure, hospital stay and healthcare costs [27].
Importantly, it has been shown diabetes patients (includ-
ing those aged ≥ 65 years) are able to mount a humoral 
immune response following pneumococcal vaccination 
which is similar (no significant differences detected) to 
that observed in subjects without diabetes, accounting 
for the ability to diabetic individuals to adequately re-
spond to such a vaccination, thereby protecting them-
selves from Pneumococcal-associated diseases [28-30].
Notably, diabetic subjects who got vaccinated with 
pneumococcal vaccine showed similar safety profile to 
euglycemic individuals who received this vaccine [28].
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Recommendations by health authorities/
scientific societies and current coverage 
rates
In Italy, both 2017-2019 NIP and 2018 AMD-SID Dia-
betes Mellitus Guidelines recommend patients with dia-
betes (either type 1 or type 2) to get vaccinated against 
pneumococcal-related infections [11-13]. In this regard, 
available recommendations state patients with diabetes 
should receive pneumococcal vaccination at least one 
time in their life, with a single revaccination for indi-
viduals aged > 64 years who got vaccinated > 5 years 
earlier [11-13].
Current NIP states pneumococcal vaccination should be 
administered all at once lifetime, in a single dose, either 
together with flu vaccination or not, and, in contrast to 
the latter, in any season of the year [11].
At this time, a relevant issue, in Italy, comes from the 
evidence of low pneumococcal vaccination coverage 
rates in patients with chronic disorders including diabe-
tes which are far away from MoH’s recommended target 
of 75%, although diabetics’ increased likelihood to suf-
fer from pneumococcal-related infections, as well as the 
well-established benefits associated with such a vaccina-
tion in these at-risk individuals [11, 31].
In fact, although In Italy pneumococcal vaccination cov-
erage rates are not routinely collected, it has been re-
ported these are quite low in the elderly, ranging from 
0.7 to 50% across different regions [31].
Importantly, current NIP’s objectives over 2017-2019 
period include a progressive increase in pneumococ-
cal vaccination coverage rates, with the goal to achieve 
MoH’s recommended target of 75% in 2019 [11].
Patients’ attitudes and/or barriers  
to pneumococcal vaccination
GPs’ advice to diabetic subjects to get vaccinated against 
pneumococcal-related infections has been shown to rep-
resent a major predictive factor for this patient group to 
adhere to pneumococcal vaccination [32,  33]. In con-
trast, diabetic patients’ reduced awareness/knowledge 
about vaccination recommendations, as well as concerns 
(from both patients’ and physicians’ side) about pneu-
mococcal vaccination-associated potential side effects 
have been shown to represent relevant factors account-
ing for the reduced uptake of this vaccination in such 
individuals [32, 33].
In summary the major points of interest are:
• Diabetic patients are more likely to develop pneu-
mococcal pneumonia and invasive disease, as well as 
their complications [24, 25].
• Hyperglycemia-associated harmful effects on im-
mune and/or pulmonary function has been hypoth-
esized to account for diabetics’ greater likelihood to 
develop pneumococcal-related infections [24].
• Both MoH and scientific societies recommend pneu-
mococcal vaccination in diabetics [11, 13]..
• Influenza vaccination has been shown effective in 
diabetic patients, resulting in reduced risk of pneu-
monia, hospitalizations, respiratory failure, as well as 
shortening hospital stay [25, 27].
• In Italy, although vaccination-associated benefits and 
available recommendations, pneumococcal vaccina-
tion coverage rates in diabetic subjects are below 
MoH’s established target of 75% [11, 31].
• Recommendations by GPs to diabetics to receive 
pneumococcal vaccination and vaccine-associated 
safety concerns by patients/HCPs represent major 
promoting and limiting factors, respectively, to dia-
betic patients’ adherence to this vaccination [32, 33].
Herpes Zoster (HZ) in patients  
with diabetes 
Susceptibility to HZ infection
Recently published studies reported diabetes represents 
a major risk factor for the development of HZ infection 
and its severe complication, namely the post-herpetic 
neuralgia (PHN) [5].
The current NIP recommends diabetes patients to get 
vaccinated also against herpes zoster (HZ) infection [11].
In Italy, vaccination against HZ is recommended and 
provided freely not only to people ≥ 65 years, but also 
to individuals suffering from chronic disorders such as 
diabetes mellitus [11].
Accordingly, a meta-analysis, conducted in the U.S., 
and based on 62 trials, reported patients with diabetes 
(especially those with type 2 diabetes [T2DM]) had an 
increased risk (by 30%) to develop HZ infection [34].
Another study (which was observational in the design) 
conducted in the U.S. showed diabetic patients were 
more likely to suffer from both HZ and PHN, which 
incidences were increased, as compared to individuals 
without diabetes, by 78% and 50%, respectively [35]. 
Consistent with findings from aforementioned trials, 
Weitzman’s et al. retrospective cohort study, found HZ 
infection and PHN were associated with some risk fac-
tors including diabetes [36]. Moreover, it has been es-
timated each year in the U.S. that 13% of all cases of 
HZ occurred in subjects with diabetes the latter has also 
been shown to be associated with an increased severity 
of HZ infection course [5, 35].
Notably, it has been shown type 1 diabetes (T1MD), and 
not only T2DM, would represent a risk factor for HZ 
occurrence, as well as this infection would be more com-
mon in women and elderly diabetic individuals and also 
in patients with diabetic vascular complications [5].
HZ infection-related impact  
and vaccination-induced benefits
Diabetes subjects, in addition to being at higher risk of 
developing PHN, have also been shown, as compared to 
subjects without diabetes, to experience increased sever-
ity and persistence of PHN, the latter known to nega-
tively affect diabetic patients’ quality of life [5].
Importantly, HZ infection has also been shown to nega-
tively affect diabetics’ glycemic control, as well as in-
crease healthcare resource utilization in this patient 
group, due to the higher number of outpatient visits, hos-
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pitalizations, antiviral medications usage, loss of work-
ing days [5].
Based on above-mentioned data, prevention of HZ in-
fection and PHN episodes in subjects with diabetes rep-
resent a key goal in these at-risk individuals and lies on 
the chance of providing such subjects with vaccination 
against HZ infection [5, 11].
To date, in Italy, anti-HZ vaccination is based on a mar-
keted live attenuated vaccine, while in the future, a new, 
recombinant adjuvated vaccine, recently approved in Eu-
rope, and already employed in the U.S. for eligible indi-
viduals (including those with diabetes), would be made 
available also in Italy and in other EU countries [5].
Recommendations by health authorities/
scientific societies and current coverage rates
Although the relevant – clinical, social and economic –
burden of HZ infection in patients with diabetes, as well 
as the proven benefits resulting from the related vacci-
nation, the current coverage rates are still low in these 
high-risk subjects [5].
In Italy, vaccination against HZ infection is currently 
recommended in individuals with diabetes by, both 
2017-2019 NIP and 2018 AMD-SID Diabetes Mellitus 
Guidelines [11, 13].
According to the current NIP, vaccination against HZ 
infection is recommended, and – actively and freely –of-
fered (in addition to elderly individuals) to subjects aged 
≥ 50 years suffering from chronic disorders such diabe-
tes [11].
The current NIP has issued, over 2017-2019 period, the 
objective of a progressive increase in HZ-related vac-
cination coverage rates, in order to reach, in 2019, the 
MoH’s recommended target of 50% [11].
In summary the major points of interest are:
• Diabetes represents a major risk factor for the onset 
of both HZ infection and PHN [5].
• Diabetes is responsible for a more severe clinical 
course of HZ infection [5].
• Diabetic patients show higher persistence and severi-
ty of PHN compared to subjects without diabetes [5].
• HZ infection has been shown to worsen diabetics’ 
glycemic control and quality of life, as well as to in-
crease related healthcare costs [5].
• Vaccination against HZ infection is recommended by 
both MoH and diabetes scientific societies, and is of-
fered freely also to diabetic subjects aged > 50 years, 
with the goal of a progressive increase in vaccination 
coverage rates across 2017-2019 [11, 13].
Other vaccinations recommended  
in diabetic individuals
Anti-meningococcal disease
Current NIP’s recommended vaccinations in diabetics 
also include meningococcal vaccination, to T1DM pa-
tients [11].
In this regard, NIP states subjects with certain diseases 
are more likely to develop meningococcal invasive in-
fection; therefore, immunization through meningococ-
cal conjugated vaccine is recommended in patients suf-
fering from disorders such as T1DM [11].
Notably, the recommendation to diabetics to receive 
meningococcal vaccination has been included, for the 
first time, in 2018 AMD-SID Diabetes Mellitus Guide-
lines recommending meningococcal vaccinations to all 
subjects with T1DM [13].
Anti-Diphteria-tetanus-pertussis (dTp)
Vaccination against diphtheria, tetanus and pertussis 
(dTp) is also included in 2017-2019 NIP and provided 
(via an active offer) as a ten-year booster, and through 
an adult-based dosage [11].
Although current NIP doesn’t specifically refer to dia-
betic patients while addressing anti-dTp vaccination, in 
contrast to the CDC (Centers for Disease Control and 
Prevention) which specifically refers to diabetics among 
individuals for whom such a vaccination is recommend-
ed, it is clear that current NIP-reported recipients (those 
aged 19-64 years) to anti-dTp vaccination also include 
patients with diabetes for whom this vaccination is rec-
ommended due to their increased likelihood to develop 
severe infections [3-5, 11, 37].
Scientific societies’ recommendations about 
adult diabetic subject-related vaccinations
To actively promote vaccinations included in the na-
tional vaccine calendar approved by the Italian Ministry 
of Health, represents a deontology obligation for each 
Physician (Italian Ministry of Health circular. March 9, 
2017. Operational aspects for the complete and consist-
ent implementation of the 2017-2019 National Immuni-
zation Plan and the related Vaccine Calendar).
These recommendations include:
• Flu vaccination to be systematically offered by GPs 
to their diabetic subjects, together with also during 
the influenza campaign, pneumococcal vaccination 
(if possible and available) to diabetic individuals.
• Systematic counseling carried out by GPs to diabetic 
patients regarding influenza and pneumococcal vac-
cinations, together with, at any time, the evaluation of 
anti-tetanus vaccination coverage, as well as advice 
provided towards anti-HZ vaccination. Moreover, as-
sessment of meningococcal vaccination coverage to 
be implemented in adults with type 1 diabetes.
• Diabetes-treating physicians and GPs, during the 
collection of patients’ history, should systematically 
assess and report within medical records, diabetic 
patients’ vaccinal status regarding the following vac-
cinations:
- anti-flu;
- anti-pneumococcal; 
- anti-diphtheria- tetanus-pertussis (dTp);
- anti-herpes zoster (HZ); 
- anti-meningococcal (T1DM patients).
• Systematic vaccination counseling performed by 
diabetes-treating physicians, together with reporting, 
within either outpatient visit-associated documenta-
tion or hospital discharge-related letter (to be provid-
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ed to diabetic patients) recommendations to receive 
the following vaccinations:
- anti-flu;
- anti-pneumococcal;
- anti-dTp;
- anti-HZ;
- anti-meningococcal (T1DM patients).
• Diabetes-treating physicians should attend educa-
tional events, organized by the related Scientific 
Societies, addressing the topic of vaccinations in 
adult patients with diabetes, in order to increase their 
knowledge & awareness about this matter.
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